How bad was that original risk-share? Sanofi had to threaten to remove their therapy from the PBS for atopic dermatitis to secure any changes, and it remains so bad that Lilly is not going to list EBGLYSS. …
This could be the canary in the coal mine, but a lot of canaries have already died
June 15, 2025 Latest NewsBioPharmaComment
Latest Video
Georgia Forrest
New Stories
-
Setting the standard for safe and accountable virtual healthcare in Australia
March 4, 2026 - - Latest News -
A system built for a past is struggling to meet the challenge of today, let alone the future
March 4, 2026 - - Latest News -
Firebrick Pharma targets breakout year in 2026 as Nasodine expansion accelerates
March 4, 2026 - - Australian Biotech -
AdAlta strengthens clinical push for breakthrough solid cancer therapy
March 4, 2026 - - Australian Biotech -
Island Pharmaceuticals deepens US biodefence ties to advance Marburg treatment
March 4, 2026 - -
PYC Therapeutics secures strong backing as retail offer adds $47 million to capital raise
March 4, 2026 - - Australian Biotech -
Alterity strengthens clinical leadership with appointment of neurologist Daniel Claassen
March 4, 2026 - - Australian Biotech